Yi Han

ORCID: 0000-0001-6847-7559
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Induction Heating and Inverter Technology
  • Cell death mechanisms and regulation
  • ATP Synthase and ATPases Research
  • Welding Techniques and Residual Stresses
  • Aluminum Alloy Microstructure Properties
  • Ubiquitin and proteasome pathways
  • RNA Interference and Gene Delivery
  • Metallurgical Processes and Thermodynamics
  • Microstructure and Mechanical Properties of Steels
  • Laser and Thermal Forming Techniques
  • Chemical Synthesis and Analysis
  • interferon and immune responses
  • Catalytic Processes in Materials Science
  • Metallurgy and Material Forming
  • Magnetic Properties and Applications
  • Advanced Welding Techniques Analysis
  • Aquaculture disease management and microbiota
  • Coastal and Marine Dynamics
  • Ferroptosis and cancer prognosis
  • Peptidase Inhibition and Analysis
  • Epigenetics and DNA Methylation
  • Cancer Immunotherapy and Biomarkers
  • RNA modifications and cancer
  • Sulfur Compounds in Biology
  • Power Systems and Technologies

Sun Yat-sen University
2013-2025

Sun Yat-sen University Cancer Center
2018-2025

North China Electric Power University
2009-2024

China Electric Power Research Institute
2009-2024

State Key Laboratory of Oncology in South China
2019-2024

Xiamen University
2024

Changzhou University
2024

Shanghai Tenth People's Hospital
2024

Tongji University
2024

Shenyang Aerospace University
2024

We report the discovery and characterization of SM-406 (compound 2), a potent orally bioavailable Smac mimetic an antagonist inhibitor apoptosis proteins (IAPs). This compound binds to XIAP, cIAP1, cIAP2 with Ki 66.4, 1.9, 5.1 nM, respectively. Compound 2 effectively antagonizes XIAP BIR3 protein in cell-free functional assay, induces rapid degradation cellular cIAP1 protein, inhibits cancer cell growth various human lines. It has good oral bioavailability mice, rats, non-human primates,...

10.1021/jm101505d article EN Journal of Medicinal Chemistry 2011-03-28

The interaction between β-catenin and B-cell CLL/lymphoma 9 (BCL9), critical for the transcriptional activity of β-catenin, is mediated by a helical segment from BCL9 large binding groove in β-catenin. Design potent, metabolically stable peptides represents an attractive approach to inhibit In this study, we report use Huisgen 1,3-dipolar cycloaddition reaction generate triazole-stapled α-helical peptides. high efficiency mild conditions "click" combined with ease synthesis necessary...

10.1021/jm201125d article EN Journal of Medicinal Chemistry 2011-12-23

Signal transducer and activator of transcription 3 (STAT3) is a factor an attractive therapeutic target for cancer other human diseases. Despite 20 years persistent research efforts, targeting STAT3 has been very challenging. We report herein the structure-based discovery potent small-molecule degraders based upon proteolysis chimera (PROTAC) concept. first designed SI-109 as potent, inhibitor SH2 domain. Employing ligands cereblon/cullin 4A E3 ligase SI-109, we obtained series PROTAC...

10.1021/acs.jmedchem.9b01530 article EN Journal of Medicinal Chemistry 2019-11-20

Combining anti-angiogenic therapy with immune checkpoint blockade anti-programmed cell death-1 (PD-1) antibodies is a promising treatment for hepatocellular carcinoma (HCC). Tyrosine kinase inhibitors are well-known agents and offer potential combination anti-PD-1 antibodies. This study investigated the possible underlying immunomodulatory mechanisms of combined therapy.HCC tissue samples RNA-sequencing (RNA-seq) were obtained from patients differential prognoses following treatment....

10.1159/000505695 article EN cc-by-nc-nd Liver Cancer 2020-01-01

Small-molecule Smac mimetics are being developed as a novel class of anticancer drugs. Recent studies have shown that target cellular inhibitor apoptosis protein (cIAP)-1/2 for degradation and induce tumor necrosis factor-alpha (TNFalpha)-dependent in cells. In this study, we investigated the mechanism action therapeutic potential two different types mimetics, monovalent SM-122 bivalent SM-164. Our data showed removal cIAP-1/2 by or small interfering RNA is not sufficient robust...

10.1158/0008-5472.can-08-2655 article EN Cancer Research 2008-11-14

Edwardsiella tarda, the causative agent of Edwardsiellosis, imposes medical challenges in both clinic and aquaculture. The emergence multidrug resistant strains makes antibiotic treatment impractical. identification molecules that facilitate or promote efficacy is high demand. In present study, we aimed to identify small whose abundance correlated with kanamycin resistance E. tarda by gas chromatography–mass spectrometry. We found fructose was greatly suppressed kanamycin-resistant strains....

10.1021/pr501285f article EN Journal of Proteome Research 2015-02-12

In this study, ZIF-8 with a rhombic dodecahedron structure was prepared by hydrothermal method. Then La(OH)3, successfully loaded onto the an immersion deposition method, to form lanthanide-based metal-organic framework (La@ZIF-8) composites. The and properties of La@ZIF-8 were verified X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), transmission (TEM), thermogravimetric analysis (TGA), zeta potential measurements. optimum process...

10.1039/c9ra10548d article EN cc-by-nc RSC Advances 2020-01-01

Abstract Colorectal cancer (CRC) patients with liver metastases usually obtain less benefit from immunotherapy, and the underlying mechanisms remain understudied. Here, we identify that fibrinogen-like protein 1 (FGL1), secreted cells hepatocytes, facilitates progression of CRC in an intraportal injection model by reducing infiltration T cells. Mechanistically, tumor-associated macrophages (TAMs) activate NF-ĸB secreting TNFα/IL-1β microenvironment transcriptionally upregulate OTU...

10.1038/s41467-023-42332-0 article EN cc-by Nature Communications 2023-10-23

We report herein the structure-based design of a class conformationally constrained, potent, cell-permeable small-molecule inhibitors to target SH2 domain in STAT3. Compound 11 (CJ-1383) binds STAT3 with K(i) value 0.95 µM, dose-dependently inhibits cellular signaling and cancer cell growth, induces apoptosis MDA-MB-468 line constitutively activated

10.1021/ml100010j article EN ACS Medicinal Chemistry Letters 2010-03-10

10.1016/j.tips.2023.12.003 article EN Trends in Pharmacological Sciences 2024-01-11

Smac mimetics are being developed as a new class of anticancer therapies. Because the single-agent activity is very limited, rational combinations represent viable strategy for their clinical development. The combination with TNF-related apoptosis inducing ligand (TRAIL) may be particularly attractive because low toxicity TRAIL to normal cells and synergistic antitumor observed combination. In this study, we have investigated synergy between potent mimetic, SM-164, in vitro vivo underlying...

10.1158/1535-7163.mct-10-0864 article EN Molecular Cancer Therapeutics 2011-03-04

Recent study suggests that auranofin (AF), a US Food and Drug Administration (FDA)-approved drug for treatment of rheumatoid arthritis, has selective anticancer activity in various experimental models. Its clinical applications cancer treatment, however, have been hampered due part to its relatively moderate as single agent. In this study, we performed high-throughput screening the FDA-approved library compounds potentiate auranofin, unexpectedly identified an anti-inflammatory celecoxib...

10.3390/cancers11070931 article EN Cancers 2019-07-03

10.1016/j.applthermaleng.2016.10.113 article EN Applied Thermal Engineering 2016-10-20

The Hippo signaling pathway plays an essential role in organ size control and tumorigenesis. Loss of signal hyper-activation the downstream oncogenic YAP are commonly observed various types cancers. We previously identified STRN3-containing PP2A phosphatase as a negative regulator MST1/2 kinases (i.e., Hippo) gastric cancer (GC), opening possibility selectively targeting PP2Aa-STRN3-MST1/2 axis to recover against cancer. Here, we further discovered 1) disulfiram (DSF), FDA-approved drug,...

10.1016/j.jbc.2024.107311 article EN cc-by Journal of Biological Chemistry 2024-04-22

Alterations in ROS metabolism and redox signaling are often observed cancer cells play a significant role tumor development drug resistance. However, the mechanisms by which alterations impact cellular sensitivity to anticancer drugs remain elusive. Here we have identified mitochondrial isoform of thioredoxin reductase 3 (mtTXNRD3), through RT-PCR microarray screen, as key molecule that confers resistance sorafenib other clinical agents. High expression mtTXNRD3 is detected drug-resistant...

10.1016/j.redox.2020.101652 article EN cc-by-nc-nd Redox Biology 2020-07-23

In this paper, a hydrangea-like Bi2WO6 material was first synthesized by hydrothermal method. Then, as carrier, NiO-Bi2WO6 composite photocatalyst successfully the method and high-temperature calcination applied to studying removal of benzothiophene (BT) from fluid catalytic cracking (FCC) gasoline. The morphology, crystal structure elemental composition catalyst were characterized scanning electron microscopy (SEM), transmission (TEM), energy-dispersive X-ray spectroscopy (EDS), diffraction...

10.1016/j.colcom.2021.100381 article EN cc-by-nc-nd Colloids and Interface Science Communications 2021-02-21
Coming Soon ...